文献速递消化道出血消化内镜

伏诺拉生对比静脉质子泵抑制剂预防高危消化性溃疡成功内镜止血后再出血的多中心随机非劣效性试验

Comparison of Vonoprazan Versus Intravenous Proton Pump Inhibitor for Prevention of High-Risk Peptic Ulcers Rebleeding After Successful Endoscopic Hemostasis: A Multicenter Randomized Noninferiority Trial.
PubMed 文献 · Gastroenterology · 2024-04-05

这项多中心随机非劣效性试验纳入194例高危消化性溃疡出血(Forrest Ia/Ib、IIa/IIb)且内镜止血成功的患者,1:1接受伏诺拉生或大剂量静脉质子泵抑制剂治疗。伏诺拉生组30天再出血率为7.1%(98例中7例),质子泵抑制剂组为10.4%(96例中10例),证实伏诺拉生非劣效于静脉质子泵抑制剂,3天和7天再出血率亦非劣效,所有次要结局两组相当。

要点

  • 高危消化性溃疡止血成功后,伏诺拉生预防30天再出血非劣效于静脉质子泵抑制剂。
  • 伏诺拉生组30天再出血率为7.1%(98例中7例),质子泵抑制剂组为10.4%(96例中10例)。
  • 3天和7天再出血率伏诺拉生组亦非劣效于质子泵抑制剂,所有次要结局两组相当。

核心结论

  • 在高危消化性溃疡出血患者中,伏诺拉生预防30天再出血的疗效非劣效于静脉质子泵抑制剂。

研究设计与样本

  • 多中心、随机、非劣效性研究,在6个中心开展,共纳入194例高危消化性溃疡出血且内镜止血成功的患者。
  • 患者按1:1随机接受伏诺拉生(20 mg每日两次共3天,随后20 mg每日一次共28天)或大剂量质子泵抑制剂(泮托拉唑静脉输注8 mg/h共3天,随后奥美拉唑20 mg每日两次共28天)。
  • 主要结局为30天再出血率,次要结局包括3天和7天再出血率、全因死亡与出血相关死亡、补救治疗率、输血、住院时长及安全性。

主要发现

  • 伏诺拉生组30天再出血率为7.1%(98例中7例),质子泵抑制剂组为10.4%(96例中10例),风险差-3.3(95%CI -11.2至4.7),非劣效性成立(10%界值内,P < .001)。
  • 伏诺拉生组3天和7天再出血率非劣效于质子泵抑制剂(Farrington and Manning检验P < .001)。
  • 所有次要结局在两组间相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: High-dose proton pump inhibitor (PPI) therapy has been recommended to prevent rebleeding of high-risk peptic ulcer (PU) after hemostasis. Vonoprazan has been proven to be noninferior to PPIs in various acid-related diseases. This study aimed to compare the efficacy of vonoprazan vs PPI for preventing high-risk PU rebleeding after hemostasis. METHODS: A multicenter, randomized, noninferiority study was conducted in 6 centers. Pre-endoscopic and endoscopic therapy were performed according to standard protocol. After successful hemostasis, patients with high-risk PU bleeding (Forrest class Ia/Ib, IIa/IIb) were randomized into 1:1 to receive vonoprazan (20 mg twice a day for 3 days, then 20 mg once a day for 28 days) or high-dose PPI (pantoprazole intravenous infusion 8 mg/h for 3 days, then omeprazole 20 mg twice a day for 28 days). The primary outcome was a 30-day rebleeding rate. Secondary outcomes included 3- and 7-day rebleeding rate, all-cause and bleeding-related mortality, rate of rescue therapy, blood transfusion, length of hospital stay, and safety. RESULTS: Of 194 patients, baseline characteristics, severity of bleeding, and stage of ulcers were comparable between the 2 groups. The 30-day rebleeding rates in vonoprazan and PPI groups were 7.1% (7 of 98) and 10.4% (10 of 96), respectively; noninferiority (within 10% margin) of vonoprazan to PPI was confirmed (%risk difference, -3.3; 95% confidence interval, -11.2 to 4.7; P < .001). The 3-day and 7-day rebleeding rates in the vonoprazan group remained noninferior to PPI (P < .001 by Farrington and Manning test). All secondary outcomes were also comparable between the 2 groups. CONCLUSION: In patients with high-risk PU bleeding, the efficacy of vonoprazan in preventing 30-day rebleeding was noninferior to intravenous PPI. (ClinicalTrials.gov, Number: NCT05005910).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Geeratragool T, Kaosombatwattana U, Boonchote A, et al. Comparison of Vonoprazan Versus Intravenous Proton Pump Inhibitor for Prevention of High-Risk Peptic Ulcers Rebleeding After Successful Endoscopic Hemostasis: A Multicenter Randomized Noninferiority Trial. Gastroenterology. 2024. PMID: 38582271. doi:10.1053/j.gastro.2024.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。